Jagsonpal Pharmaceuticals Limited

Equities

JAGSNPHARM

INE048B01027

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:47 2024-04-26 am EDT 5-day change 1st Jan Change
343.6 INR +3.06% Intraday chart for Jagsonpal Pharmaceuticals Limited +6.31% -11.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jagsonpal Pharmaceuticals Limited Launches Queezy-ER® CI
Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Jagsonpal Pharmaceuticals' Net Profit Soars in Fiscal Q1 MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023 CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others completed the acquisition of 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar. CI
Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Jagsonpal Pharmaceuticals Limited Announces Executive Changes CI
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm cancelled the acquisition of 26% stake in Jagsonpal Pharmaceuticals Limited. CI
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Infinity Holdings to Acquire Controlling Stake in Jagsonpal Pharmaceuticals for $36 Million MT
Infinity Holdings Sidecar I and Infinity Holdings, managed by Infinity Investment Management, Investment Arm and others entered into a share purchase agreement to acquire 43.73% stake in Jagsonpal Pharmaceuticals Limited from Aresko Progressive Private Limited and Rajpal Singh Kochhar for INR 2.7 billion. CI
Infinity Investment Management made an offer to acquire 26% stake in Jagsonpal Pharmaceuticals Limited for INR 1.6 billion. CI
Jagsonpal Pharmaceuticals Limited Enters into an Agreement with Suvinys Developers Private Limited for Supply of Product Dydrogesterone CI
Jagsonpal Pharmaceuticals Names New CFO MT
Jagsonpal Pharmaceuticals Appoints New CFO MT
Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Jagsonpal Pharmaceuticals CFO Resigns MT
Chart Jagsonpal Pharmaceuticals Limited
More charts
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Company’s therapy areas include gynecology, orthopedics, and others.
More about the company
  1. Stock Market
  2. Equities
  3. JAGSNPHARM Stock
  4. News Jagsonpal Pharmaceuticals Limited
  5. Jagsonpal Pharmaceuticals : Logs Over 82% Jump in Net Profit in Fiscal Q2